Substituted bicyclic compounds

US11058696B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Alaric J. Dyckman · Lawrenceville, US
• T. G. Murali Dhar · Newtown, US
• Hai-Yun Xiao · Montgomery, US
• John L. Gilmore · Yardley, US
• Michael G. Yang · Narberth, US
• Zili Xiao · Plainsboro, US
• David Marcoux · Pennington, US

Key dates

• Filing date: May 21, 2020
• Grant date: Jul 13, 2021
• Expiry date: May 21, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2603/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.